Corcept Therapeutics Inc
Corcept Therapeutics Inc (CORT) Straddle
CORT straddle scan found 125 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 51.7%.
Read more
Trading a CORT straddle lets you take a pure volatility position on Corcept Therapeutics Inc without committing to a direction. Corcept Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CORT straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on CORT profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Corcept Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CORT straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the CORT straddle is the cleanest expression of that view. Our scanner prices every CORT straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CORT straddle into a catalyst or short a CORT straddle to harvest decay, the options straddle setups that matter are all in one place.
| Nov 20, 2026 | 170.00 | $58.55 | 65 | 12% | 51.7% | $228.55 | $111.45 | 0 |
| Jan 21, 2028 | 180.00 | $82.00 | 492 | 12% | 50.1% | $262.00 | $98.00 | 0 |
| Oct 16, 2026 | 125.00 | $15.13 | 30 | 12% | 49.9% | $140.13 | $109.88 | 5 |
| Jan 21, 2028 | 175.00 | $78.35 | 492 | 12% | 49.6% | $253.35 | $96.65 | 0 |
| Oct 16, 2026 | 130.00 | $19.45 | 30 | 12% | 49.2% | $149.45 | $110.55 | 3 |
| Jan 15, 2027 | 180.00 | $71.20 | 121 | 12% | 49.1% | $251.20 | $108.80 | 0 |
| Oct 16, 2026 | 120.00 | $12.40 | 30 | 12% | 48.8% | $132.40 | $107.60 | 6 |
| Jan 21, 2028 | 170.00 | $75.25 | 492 | 12% | 48.7% | $245.25 | $94.75 | 0 |
| Feb 19, 2027 | 180.00 | $72.80 | 156 | 12% | 48.1% | $252.80 | $107.20 | 0 |
| Nov 20, 2026 | 145.00 | $35.78 | 65 | 12% | 47.9% | $180.78 | $109.23 | 0 |
As of September 17, 2026
Find the right straddle before volatility moves
Track CORT straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→